DRAPER, Utah, May 4, 2026
Ortho Development Corporation (ODEV) has announced the full commercial launch of the Trivicta® Hip Stem, a cementless triple-taper femoral implant system designed for primary total hip arthroplasty, now available across the United States through its authorized distribution network. This milestone marks a significant advancement in orthopedic implant technology, reinforcing the company’s commitment to delivering high-performance surgical solutions that enhance patient mobility and long-term clinical outcomes.
Advanced Implant Design Enhances Stability and Osteointegration
The Trivicta® Hip Stem introduces a refined triple-taper femoral design, engineered to improve implant stability, anatomical fit, and surgical efficiency. A key innovation is the application of a 35 μm hydroxyapatite coating over sintered titanium beads, which is specifically designed to promote early osteointegration, a critical factor for long-term implant fixation and success.
The system also incorporates standard and extended offset options, enabling surgeons to achieve accurate lateralization without altering leg length, an important consideration in maintaining patient biomechanics post-surgery. Additionally, progressive neck lengths and optimized distal geometry allow for better adaptation to a wide range of femoral anatomies, enhancing the versatility of the implant across diverse patient populations.
These design enhancements reflect a growing trend in MedTech innovation, where material science and biomechanical engineering are combined to improve surgical outcomes and reduce complications in joint replacement procedures.
Advertisement
Streamlined Surgical Workflow and Precision Instrumentation
The Trivicta system also focuses on improving intraoperative efficiency and reproducibility through its hybrid broach system, which features integrated anterior and posterior compaction teeth. This design helps to preserve bone integrity while ensuring accurate implant seating, addressing key challenges in orthopedic surgery.
Furthermore, the inclusion of modular instrumentation and incremental stem sizing supports consistent implant positioning across multiple surgical approaches, reducing variability and enhancing procedural reliability. These features are particularly important in modern orthopedic practice, where precision and reproducibility are essential for optimizing patient outcomes and minimizing revision rates.
Clinical feedback from early adopters has highlighted the system’s ease of use and effective implant integration, with surgeons reporting strong evidence of bone ingrowth and improved handling during procedures. Such real-world validation underscores the importance of clinician-driven design and iterative product development in advancing medical device innovation.
Expanding Orthopedic Innovation and Market Impact
The full U.S. launch of Trivicta strengthens Ortho Development’s position in the orthopedic implant market, particularly in the area of hip replacement solutions, which continues to see increasing demand due to aging populations and rising rates of degenerative joint diseases. By offering a system that combines clinical insight, engineering precision, and advanced biomaterials, the company aims to address both surgeon needs and patient expectations for improved mobility and faster recovery.
As healthcare systems continue to prioritize value-based care and long-term patient outcomes, innovations such as Trivicta play a critical role in delivering durable, reliable, and cost-effective orthopedic solutions. The system’s emphasis on biological integration, surgical efficiency, and anatomical adaptability aligns with broader trends in next-generation implant development.
Ortho Development’s continued investment in research, development, and surgeon collaboration highlights the evolving landscape of MedTech, where innovation is driven by the integration of clinical expertise, advanced materials, and precision engineering.
Source: Ortho Development press release
